Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buspirone for Dysphagia in Poor Esophageal Motility
NCT05629325Phase 4Recruiting
- Sponsor
- UZ Leuven
- Start
- Jul 2021
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in dysphagia and esophageal motility disorder (EMD) comparing Buspirone First with Placebo First (2 arms). Primary endpoint: Distal Contractile Integral (5ml supine) at 4 weeks. Started Jul 2021; status: recruiting.
02
Drugs
buspirone
03
Conditions
dysphagiaesophageal motility disorder (EMD)
Beyond the preview
Go deeper on NCT05629325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05629325.